1. At a Glance – The Pharma Comeback That Feels Too Good to Be True
If Bollywood made a finance movie, Wanbury would be that “once bankrupt, now billionaire” character who suddenly shows up in a Lamborghini… but you still wonder — bhai paisa kahan se aaya?
Because here’s what we’re dealing with:
- Profit growth: +1,194% YoY
- ROE: 66.9% (yes, not a typo)
- P/E: 12.4 vs industry ~27
- API dominance in Metformin + Sertraline (~85–90% revenue concentration)
- Promoter pledge: 62.2% (👀)
So what is Wanbury really?
A:
- Turnaround masterclass?
- Hidden pharma gem?
- Or a balance sheet juggling act that hasn’t fully landed yet?
Because when a company goes from:
- Negative net worth
➡️ to
- ₹65 Cr PAT
➡️ with
- high-cost debt + heavy pledging
…it deserves a deeper investigation.
This isn’t a story. This is a financial thriller.
And somewhere between Brazil approvals, API dominance, and ₹200 Cr NCD debt… lies the truth.
Ready to decode it?
2. Introduction – From ICU to Gym Body Transformation
Wanbury is basically that patient who was on ventilator in 2020… and now is posting gym selfies on Instagram saying “hard work pays off 💪”.
Let’s rewind:
- Heavy debt
- European business struggles
- Negative net worth
- Corporate debt restructuring
Then suddenly:
- Asset sales (₹87 Cr to Cipla)
- Equity infusion
- Debt refinancing
- Operational improvements
And BOOM — turnaround.
Now:
- EBITDA margins doubled (~5% → ~13%)
- PAT positive and growing
- Export-driven stable revenue
But here’s the twist…
Even after all this:
- Debt still exists
- Interest cost still high
- Promoter pledge still scary
So question is:
👉 Is this a clean recovery… or just Phase 1 of recovery?
3. Business Model – WTF Do They Even Do?
Let’s simplify:
Wanbury = API factory + branded medicines side hustle
Core Business:
- API (Active Pharmaceutical Ingredients)
- Raw material for medicines
- Exported globally (50+ countries)
- ~87–88% of revenue
- Formulations
- Branded medicines in India
- ~12–13% of revenue
API Dominance (The Real Money Machine)
- Metformin → Anti-diabetic (50% revenue)
- Sertraline → Anti-depressant (40% revenue)
Together:
👉 ~90% of API revenue
Yes, ONE bad pricing cycle… and business sneezes.
Business Reality
Think of Wanbury like:
A restaurant where 90% revenue comes from just “Paneer Butter Masala”
Great when demand is high…
Dangerous when customers switch diet.
So question:
👉 Would you trust a pharma company dependent on just 2 molecules?
4. Financials Overview
Quarterly Snapshot
